Annual prostate cancer mortality was 1.3–2.1 times higher in black than white Americans in all four regions before mass utilization of PSA, with at least double the prostate cancer death rate in black versus white Americans in Atlanta, Detroit, and San Francisco. This evidence concerns the gene KLK3 and prostate carcinoma.